{ "items" : [
    { "id" : "http://webisa.webdatacommons.org/prov/440444509"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/183381999" ] } },

    { "id" : "http://webisa.webdatacommons.org/183381999"
      "properties" : {
        "http://www.w3.org/1999/02/22-rdf-syntax-ns#type" : [ "http://www.w3.org/ns/prov#Entity" ] ,
        "http://www.w3.org/ns/prov#value" : [ "However, issues such as stroke, paravalvular leak and pacemaker need remain, and the unknown limitations of TAVR, including durability and undefined options for reintervention for prosthesis dysfunction, must be addressed before this therapy can be extended to younger, lower risk patients." ] ,
        "http://www.w3.org/ns/prov#wasQuotedFrom" : [ "science.gov" ] } },

    { "id" : "http://webisa.webdatacommons.org/prov/113428108"
      "properties" : {
        "http://www.w3.org/ns/prov#wasDerivedFrom" : [ "http://webisa.webdatacommons.org/183381999"] } } }
